Invizyne Technologies INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
eXoZymes Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational cash burn, leading to substantial doubt about its ability to continue as a going concern.
eXoZymes Inc. reported a net loss of $2.37 million for Q1 2026, with a significant increase in R&D costs, while cash reserves decreased by over 50%.
eXoZymes Inc. reported a significant increase in net losses and cash burn for the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
eXoZymes Inc. reported a significantly widened net loss and increased cash burn for Q2 2025, raising substantial doubt about its ability to continue as a going concern despite new grant awards.
10-Q: eXoZymes Inc. Reports Q1 2025 Results: Net Loss Widens Amid Increased R&D and Administrative Costs
eXoZymes Inc. reports a net loss of $1.86 million for Q1 2025, compared to a $1.01 million loss in Q1 2024, driven by increased operating costs.
Invizyne Technologies reported its Q3 2024 financial results, noting increased operating costs and a net loss, while also highlighting its recent IPO and future growth plans.